SS
CTSO icon

Steve Schonfeld’s Cytosorbents Corp CTSO Stock Holding History

Steve Schonfeld’s Portfolio CTSO Stock Details CTSO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-22,935
Closed -$50K – 2992
2022
Q2 		$50K Buy
22,935
+9,235
+67% +$21.2K ﹤0.01% 2224
2022
Q1 		$43K Buy
+13,700
New +$49.1K ﹤0.01% 2354

Other funds holding CTSO

SC
Skylands Capital Milwaukee, Wisconsin $814M AUM 32.37% 1-Year Est. Return
AC
Avenir Corporation Alexandria, Virginia $821M AUM 4.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.81B AUM 83.9% 1-Year Est. Return
SIG
Sargent Investment Group Bethesda, Maryland $832M AUM 24.89% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Steve Schonfeld's CTSO Position: Q3 2022 in Review

Steve Schonfeld sold out of Cytosorbents Corp (CTSO) in Q3 2022, closing a stake of 22,935 shares — an estimated $50K sold.

Steve Schonfeld first reported a position in CTSO in Q1 2022 and held it in 2 quarters. The position peaked at $50K in Q2 2022. 60 funds tracked by Wall St. Rank hold CTSO as of Q3 2022.

  • Steve Schonfeld reported no remaining Cytosorbents Corp position as of Q3 2022 after selling out during the quarter.
  • Steve Schonfeld sold 22,935 Cytosorbents Corp shares in Q3 2022, an estimated $50K.
  • Steve Schonfeld first reported a position in Cytosorbents Corp in Q1 2022 and held it in 2 quarters.
  • Steve Schonfeld's Cytosorbents Corp position peaked at $50K in Q2 2022.
  • 60 funds tracked by Wall St. Rank held Cytosorbents Corp as of Q3 2022.

Based on Schonfeld Strategic Advisors's 13F filing for Q3 2022, filed 14 Nov 2022.